Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 575 of 2529 entries
View as:

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Phase: N/A Priority: Normal
NCT ID: NCT00553358 Org: User:
Start: 01/05/08 End: 12/23/19 Due: 12/23/20

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT00901979 Org: User:
Start: 04/30/09 End: 06/30/10 Due: 06/30/11

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Phase: N/A Priority: Normal
NCT ID: NCT06240741 Org: User:
Start: 03/21/24 End: 12/27/24 Due: 12/27/25

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01201356 Org: User:
Start: 09/13/10 End: 10/19/18 Due: 10/19/19

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Phase: N/A Priority: Normal
NCT ID: NCT06156683 Org: User:
Start: 06/30/24 End: 02/01/28 Due: 02/01/29

CAR-T Long Term Follow Up (LTFU) Study

Phase: N/A Priority: Normal
NCT ID: NCT02445222 Org: User:
Start: 11/02/15 End: 02/22/36 Due: 02/22/37

A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

Phase: N/A Priority: Normal
NCT ID: NCT07027163 Org: User:
Start: 06/01/23 End: 09/01/23 Due: 09/01/24

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00514514 Org: User:
Start: 07/31/07 End: 06/30/15 Due: 06/30/16

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04237649 Org: User:
Start: 02/20/20 End: 09/15/23 Due: 09/15/24

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Phase: N/A Priority: Normal
NCT ID: NCT03955445 Org: User:
Start: 10/03/19 End: 05/30/36 Due: 05/30/37

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02074995 Org: User:
Start: 02/28/14 End: 01/31/15 Due: 01/31/16

Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00150046 Org: User:
Start: 12/31/04 End: - Due: -

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT06597006 Org: User:
Start: 02/28/25 End: 04/15/29 Due: 04/15/30

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Phase: N/A Priority: Normal
NCT ID: NCT06751238 Org: User:
Start: 06/13/25 End: 04/20/31 Due: 04/20/32

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Phase: N/A Priority: Normal
NCT ID: NCT00934544 Org: User:
Start: 07/01/09 End: 03/04/15 Due: 03/04/16

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01578928 Org: User:
Start: 05/31/12 End: 05/31/14 Due: 05/31/15

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03172936 Org: User:
Start: 09/08/17 End: 12/18/20 Due: 12/18/21

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04154787 Org: User:
Start: 11/23/19 End: 01/20/23 Due: 01/20/24

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Phase: N/A Priority: Normal
NCT ID: NCT06868290 Org: User:
Start: 03/13/25 End: 05/24/30 Due: 05/24/31

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Phase: N/A Priority: Normal
NCT ID: NCT02008890 Org: User:
Start: 12/26/13 End: 05/31/17 Due: 05/31/18

Fingolimod -Response According to Coping - Evaluation

Phase: N/A Priority: Normal
NCT ID: NCT01420055 Org: User:
Start: 08/31/11 End: 06/30/13 Due: 06/30/14

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00273312 Org: User:
Start: 01/31/06 End: - Due: -

Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.

Phase: N/A Priority: Normal
NCT ID: NCT01744028 Org: User:
Start: 06/30/12 End: 01/31/14 Due: 01/31/15

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02161562 Org: User:
Start: 08/01/14 End: 11/03/16 Due: 11/03/17

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Phase: N/A Priority: Normal
NCT ID: NCT02474082 Org: User:
Start: 04/30/15 End: 06/30/16 Due: 06/30/17